Catalyst Pharmaceuticals (CPRX) Q4 2025 earnings review
Core Growth Masks Q4 Profit Squeeze; Massive Margin Tailwind Arrives in 2026
Catalyst delivered 'record' Q4 revenues of $152.6M (+7.6% YoY), but the top-line beat obscures a notable bottom-line miss. GAAP Net Income actually reversed, falling 5.8% YoY to $52.7M. The culprit? The highly profitable FYCOMPA legacy business fell off a generic cliff, while SG&A expenses ballooned 20.8% to support two separate sales forces. However, the 2026 outlook is incredibly bullish. FYCOMPA's decline is fully priced in, and Catalyst's promoted products (FIRDAPSE and AGAMREE) are accelerating rapidly. More importantly, an under-the-radar structural change—a massive drop in FIRDAPSE royalty obligations starting January 2026—sets the stage for violent margin expansion in the year ahead.
🐂 Bull Case
Starting late January 2026, the maximum royalty rate Catalyst pays on FIRDAPSE plummets from 18.5% to just 6%. With FIRDAPSE guided to hit ~$442M in 2026, this translates to tens of millions in pure incremental profit dropping straight to the bottom line.
AGAMREE is a certified hit, growing 67% YoY in Q4 to $35.3M. FIRDAPSE continues to defy gravity, posting 18.3% YoY growth. 2026 guidance implies >20% growth for both assets, proving Catalyst's commercial execution is elite.
🐻 Bear Case
Total revenue growth is decelerating (down to 7.6% in Q4 from 43.6% in Q1). Meanwhile, SG&A is accelerating, climbing to $53.4M in Q4. This negative divergence caused net income to shrink YoY.
Catalyst has built a $709M cash hoard and reviewed over 100 targets in 2025 without pulling the trigger. As the cash pile grows, so does the pressure to acquire a value-accretive asset in a challenging macro environment.
⚖️ Verdict: 🟢
Bullish. The Q4 profit dip is a temporary transition artifact as FYCOMPA phases out. The underlying engine—FIRDAPSE and AGAMREE volume paired with a dramatic 2026 royalty reduction—sets up a highly lucrative year ahead.
Key Themes
The Hidden Margin Catalyst: FIRDAPSE Royalty Plunge
The most important data point in this release isn't revenue; it's cost of goods. Due to the expiration of tiered royalties and the 7-year anniversary of FDA approval, Catalyst's royalty burden on FIRDAPSE U.S. sales drops from a maximum of 18.5% down to a flat 6% starting January 26, 2026. This structural cost removal will act as a massive profit accelerator throughout FY26, vastly outstripping normal operating leverage.
FYCOMPA Falls Off the Generic Cliff
The trend for FYCOMPA is officially reversing. Product revenue crashed from $38.2M in 24Q4 to $19.6M in 25Q4 due to the entry of multiple generic versions. Management's 2026 guidance of $40M-$45M implies a ~60% annual revenue haircut. While expected, the loss of this high-margin legacy revenue is what dragged Q4 total profitability downward.
AGAMREE's Accelerating Commercial Momentum
AGAMREE remains a foundational growth pillar. Q4 sales hit $35.3M (+67.5% YoY), reflecting deep market penetration and high retention in DMD. 2026 guidance points to $140M-$150M, indicating stable, high-double-digit growth as the dedicated sales force deepens adoption in Centers of Excellence.
SG&A Expense Creep
While management touts revenue records, SG&A expense is outstripping sales growth. Q4 SG&A jumped 20.8% YoY to $53.4M (compared to 7.6% total revenue growth). The company cites increased commercial activities for the dual sales forces and M&A evaluations. If this run-rate persists, it could blunt the impact of the impending gross margin improvements.
The $709M M&A Waiting Game
Catalyst evaluated over 100 clinical-stage acquisition targets in 2025 but executed zero deals. While management notes a favorable macro 'buying environment' for rare disease assets, the cash pile has swelled to $709M. The launch of a $200M buyback (with $25.3M executed in Q4) shows a willingness to return capital, but investors are waiting for the 'buy and build' strategy to land its next flagship asset.
Other KPIs
Reversing. Down 5.8% YoY from $55.9M in 24Q4. This directly contradicts the bullish top-line narrative and highlights the margin pressure from FYCOMPA's decline and rising SG&A costs. Diluted EPS fell to $0.41 from $0.44.
Accelerating. Up 37% YoY from $517.6M. Note that this balance was artificially inflated by a $27M customer payment that shifted from late December to early January due to revised contract terms. The balance sheet remains pristine with zero funded debt.
Guidance
Stable growth. The midpoint ($630M) implies roughly 7% YoY growth vs FY25 ($589M). This appears artificially low because it blends 20%+ growth in the core portfolio with a ~60% collapse in FYCOMPA.
Accelerating. Implies 21.4% to 25.6% YoY growth. This is a tremendous vote of confidence in the core asset, driven by lifecycle management and penetration into the oncology segment (Cancer-Associated LEMS).
Accelerating. Implies 19.6% to 28.1% YoY growth. Demonstrates that the drug is successfully transitioning from initial launch bolus to sustained, durable market share capture.
Key Questions
SG&A Run-Rate and Margin Targets
With the massive FIRDAPSE royalty reduction coming in early 2026, how much of that gross margin improvement will be allowed to flow to operating income versus being reinvested into the elevated SG&A structure we saw in Q4?
M&A Evaluation Constraints
Management noted evaluating over 100 targets in 2025 without a deal. Is the constraint valuation mismatch, lack of clinical differentiation, or an intentional pause to focus on the AGAMREE rollout?
Oncology Care Pathway Execution
The long-term FIRDAPSE bull case relies heavily on the Cancer-Associated LEMS market. How many oncology practices have formally adopted VGCC antibody screening protocols since the NCCN guidelines were updated?